Literature DB >> 8665385

Seroepidemiological study of retroviruses (HTLV-I/II, HIV-1, HIV-2) in the Department of Atacora, northern Benin.

D Houinato1, M Verdier, R Josse, T Zohoun, L Letenneur, R Salamon, F Denis, P M Preux.   

Abstract

A seroepidemiological survey to determine the prevalence of retrovirus infection (HTLV-I/II, HIV-1, HIV-2) by representative sampling of the general population in the Department of Atacora in north-western Benin is reported. The seroprevalence rate of HTLV-I in this sample was at 1.86% (95% CI 1.20-2.52%). This is in agreement with prevalence rates reported from neighbouring countries of the sub-region. No sera were found positive for HTLV-II. Seropositivity to HIV-1 was 0.3%; HIV-2 seropositivity was not encountered.

Entities:  

Mesh:

Year:  1996        PMID: 8665385     DOI: 10.1111/j.1365-3156.1996.tb00027.x

Source DB:  PubMed          Journal:  Trop Med Int Health        ISSN: 1360-2276            Impact factor:   2.622


  4 in total

1.  Epidemiological Aspects and World Distribution of HTLV-1 Infection.

Authors:  Antoine Gessain; Olivier Cassar
Journal:  Front Microbiol       Date:  2012-11-15       Impact factor: 5.640

2.  Prevalence of human T-lymphotropic virus 1/2 in Nigeria's capital territory and meta-analysis of Nigerian studies.

Authors:  Nneoma Confidence JeanStephanie Anyanwu; Elijah Ekah Ella; Maryam Aminu; Maleeha Azam; Muhammad Ajmal; Haruna Makonjuola Kazeem
Journal:  SAGE Open Med       Date:  2019-04-16

Review 3.  Seroprevalence of HTLV-1 and HTLV-2 amongst mothers and children in Malawi within the context of a systematic review and meta-analysis of HTLV seroprevalence in Africa.

Authors:  James M Fox; Nora Mutalima; Elizabeth Molyneux; Lucy M Carpenter; Graham P Taylor; Martin Bland; Robert Newton; Fabiola Martin
Journal:  Trop Med Int Health       Date:  2016-02-03       Impact factor: 2.622

Review 4.  Re-emergence of human T-lymphotropic viruses in West Africa.

Authors:  Nneoma Confidence JeanStephanie Anyanwu; Elijah Ekah Ella; Aghogho Ohwofasa; Maryam Aminu
Journal:  Braz J Infect Dis       Date:  2018-06-05       Impact factor: 3.257

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.